Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BPC-157 and Larazotide — mechanism, dosing, side effects, legal status, and pricing.
BPC-157 is a synthetic pentadecapeptide (sequence GEPPPGKPADDAGLV) derived from a 15-amino-acid fragment of body protection compound (BPC), a protein isolated from human gastric juice. It is research-only, not approved by the FDA or any major regulator for human use, and almost all published evidence comes from rodent models.
Larazotide is a synthetic linear octapeptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) structurally derived from the Vibrio cholerae zonula occludens toxin. It is proposed to act on the zonulin/tight-junction signaling pathway, interrupting gliadin-triggered intestinal barrier disruption by preserving tight-junction integrity locally in the gut lumen. Larazotide has been studied in multiple human trials for celiac disease under the development codes AT-1001, INN-202, and SPD550, but has never received FDA or EMA approval; a Phase 3 trial (NCT03569007) was terminated by the sponsor in 2022 with no results posted. It is not systemically absorbed and is available only as a research chemical.
BPC-157
Larazotide
Category
Legal Status
Mechanism
Dose Range
Route
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BPC-157
Larazotide
COA corpus from Disclosed Labs — independently tested batches only.
BPC-157
334
COAs
99.3%
Avg purity
16
Labs
Larazotide
1
COAs
98.3%
Avg purity
1
Labs
BPC-157 is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Larazotide remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Extensive rodent data from the Sikiric group and others report accelerated healing of tendon, ligament, muscle, and gastrointestinal injury, plus cytoprotective effects in models of NSAID and alcohol damage (PMID 21548867, 30915550). Preclinical tendon studies demonstrate enhanced growth hormone receptor expression in fibroblasts (PMID 25415472) and promote tendon outgrowth, cell survival, and cell migration (PMID 21030672). Published human clinical evidence is limited; an early oral formulation (PL 14736) was explored for inflammatory bowel disease but has not progressed to approval. No peer-reviewed trial validates the injectable doses (200–500 mcg) commonly used on the grey market, and pharmacokinetics and long-term safety in humans are not well characterized.
Key references
Larazotide has been studied in multiple completed human trials for celiac disease but has never received FDA or EMA approval. A Phase 1 single-dose study (Paterson et al. 2007, PMID 17697209) confirmed no systemic absorption. Phase 2 gluten-challenge trials (Leffler et al. 2012, PMID 22825365, n=86, doses 0.25/1/4/8 mg TID) did not meet the primary endpoint (intestinal permeability) due to high variability, though lower doses limited symptom worsening. A Phase 2b trial (Leffler et al. 2015, PMID 25683116, ~342 patients, no gluten challenge) met its primary endpoint at the 0.5 mg TID dose, showing symptom improvement versus placebo with an inverse dose-response. The Phase 3 CeDLara trial (NCT03569007, 307 patients, 0.25 mg and 0.5 mg TID) was terminated by the sponsor in 2022 for futility/impractically large required sample size, with no results posted. Across trials, no serious drug-related adverse events or hepatic/renal/bone toxicity signals were reported; headache and urinary tract infection were the most common adverse events without consistent excess versus placebo. In preclinical models, larazotide reduced gliadin-induced paracellular permeability and preserved tight-junction protein localization in Caco-2 human intestinal cell monolayers, prevented gliadin-induced permeability increases and reduced macrophage infiltration in HLA-DQ8 transgenic mice, and accelerated barrier recovery in a porcine jejunum ischemia-reperfusion injury model.
BPC-157 (Recovery) and Larazotide (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Frequency
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Key references
Disclosed Labs